.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,763,483

« Back to Dashboard
Patent 5,763,483 protects TAMIFLU and is included in two NDAs. There have been three Paragraph IV challenges on Tamiflu.

Protection for TAMIFLU has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,763,483

Title: Carbocyclic compounds
Abstract:Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.
Inventor(s): Bischofberger; Norbert W. (San Carlos, CA), Kim; Choung U. (San Carlos, CA), Lew; Willard (San Mateo, CA), Liu; Hongtao (Foster City, CA), Williams; Matthew A. (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:08/774,345
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 39th percentile
Forward Citations: 8th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Roche
TAMIFLU
oseltamivir phosphate
FOR SUSPENSION;ORAL021246-002Mar 21, 2011RXYes5,763,483*PED► subscribeY
Roche
TAMIFLU
oseltamivir phosphate
FOR SUSPENSION;ORAL021246-001Dec 14, 2000DISCNNo5,763,483*PED► subscribeY
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-003Jul 2, 2007RXNo5,763,483*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc